Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Favipiravir vs Hydroxychloroquine for COVID-19
NCT04387760Phase 2Completed
- Sponsor
- RCSI Medical University of Bahrain
- Start
- Aug 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of favipiravir in coronavirus disease 2019 (COVID-19), sponsored by RCSI Medical University of Bahrain. Started Aug 2020; status: completed.
02
Drugs
favipiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04387760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04387760.